US Patent

US8450287 — Topical ophthalmic compositions containing tobramycin and dexamethasone

Formulation · Assigned to Alcon Research LLC · Expires 2027-12-19 · 2y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a topical ophthalmic composition containing tobramycin and dexamethasone, specifically designed for longer ocular retention and improved suspension of dexamethasone.

USPTO Abstract

Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.

Drugs covered by this patent

Patent Metadata

Patent number
US8450287
Jurisdiction
US
Classification
Formulation
Expires
2027-12-19
Drug substance claim
No
Drug product claim
Yes
Assignee
Alcon Research LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.